Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Precision BioSciences, Inc. - Common Stock
(NQ:
DTIL
)
4.500
UNCHANGED
Streaming Delayed Price
Updated: 1:00 PM EST, Dec 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
63,788
Open
4.500
Bid (Size)
4.350 (3)
Ask (Size)
4.780 (10)
Prev. Close
4.500
Today's Range
4.445 - 4.650
52wk Range
4.130 - 19.43
Shares Outstanding
113,793,338
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Precision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis B
December 18, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming November Investor Conferences
November 21, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Performance
YTD
-59.46%
-59.46%
1 Month
-37.85%
-37.85%
3 Month
-51.03%
-51.03%
6 Month
-52.98%
-52.98%
1 Year
-59.04%
-59.04%
More News
Read More
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
November 15, 2024
From
Precision BioSciences
Via
Business Wire
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 04, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Third Quarter Results on November 4, 2024
October 29, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
October 28, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
October 24, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
October 24, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
October 21, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
October 16, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at the Upcoming H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference
October 03, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Submits First Clinical Trial Applications to Initiate Phase 1 Trial for PBGENE-HBV for the Treatment of Chronic Hepatitis B
September 30, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Strengthens Senior Leadership Team Ahead of Anticipated PBGENE-HBV Clinical Execution
September 12, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming H.C. Wainwright 26th Annual Global Healthcare Conference
September 04, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
September 03, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
August 09, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
7 Biotech Stocks to Buy for Their Game-Changing Potential
August 08, 2024
Via
InvestorPlace
Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update
August 01, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Participate in Upcoming August Investor Conferences
July 31, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Report Second Quarter Results on August 1, 2024
July 29, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences to Present at the Upcoming JonesTrading Healthcare Seaside Summit
July 08, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces its Addition to the Russell Microcap® Index
July 01, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Announces Presentation at UMDF Mitochondrial Medicine 2024 Supporting Advancement of PBGENE-PMM Program Towards IND and/or CTA in 2025
June 27, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Precision BioSciences Expands Hepatitis Scientific Advisory Board with Addition of World-Class Clinical Investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., MPH, as PBGENE-HBV Program Nears Clinical Readiness
June 20, 2024
From
Precision BioSciences, Inc.
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.